A first-of-its-kind clinical trial is offering new hope to millions of people living with advanced dry macular degeneration, one of the leading causes of permanent vision loss among adults over 60. Researchers have successfully transplanted adult retinal stem cells into patients, with early results indicating measurable improvements in vision and no major safety concerns.
The trial, published in Cell Stem Cell, involved a phase 1/2a study where scientists used retinal pigment epithelial stem cells derived from adult postmortem eye tissue. These cells were transplanted into the eyes of patients with severe AMD, a condition that damages the macula—the central part of the retina responsible for sharp, detailed, and color vision.
AMD affects nearly 20 million adults in the United States alone, with millions more worldwide. Until now, advanced dry AMD has had no effective treatment, leaving patients with progressive and irreversible central vision loss. The success of this trial marks a potential turning point in ophthalmology, suggesting that stem cell therapy could restore vision once thought permanently lost.
Experts emphasize that while these results are encouraging, the therapy remains in early stages. Larger trials will be required to confirm long-term safety and effectiveness before the treatment can be widely adopted. Nevertheless, the findings have generated optimism among clinicians and patients alike, as they point to the possibility of reversing a condition long considered incurable.
This breakthrough highlights the growing role of regenerative medicine in tackling age-related diseases. If subsequent trials confirm the benefits, stem cell therapy could become a transformative solution for millions living with AMD, reshaping the future of vision care.
